NCT03799718Phase 2Completed

Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS

Study sponsor: Brainstorm-Cell Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2021-03-11Actual
Enrollment · participants23Actual
Source updated2023-12-04Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.